



Market Announcement

22 April 2020

Cardiex Limited (ASX: CDX) – Suspension from Official Quotation

Description

The securities of Cardiex Limited ('CDX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding its progress in relation to a joint development agreement with a partner organisation.

Issued by

Corey Lian

Adviser, Listings Compliance (Sydney)



22 April 2020

Mr Corey Lian

By Email

To: Corey.Lian@asx.com.au ; tradinghaltssydney@asx.com.au

Dear Sir,

**RE: Request for Voluntary Suspension on Securities of CardieX Limited
(ASX: CDX CDXO)**

Pursuant to Listing Rule 17.2, pending an announcement regarding progress made in conjunction with its Joint Development Agreement with Mobvoi, CDX formally applies for a voluntary suspension to be put in place immediately.

The suspension is requested to be in place until the earlier of commencement of trade 23 April 2020 or when that announcement is released to the market.

CDX is not aware of any reason why the Company's request for a voluntary suspension should not be granted.

Yours sincerely,

CARDIEX LIMITED

A handwritten signature in blue ink, appearing to read "Jarrod White", written over a blue circular stamp or watermark.

**JARROD WHITE
CHIEF FINANCIAL OFFICER | COMPANY SECRETARY**

For more information please contact:

Chief Financial Officer
Jarrod White
Ph: +61 8296 0000
jwhite@cardiex.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231
peter@nwrcommunications.com.au

About CardieX

CardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related disorders.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.



In September 2019 CardieX signed a joint development agreement with Mobvoi Information Technology Co. Ltd (Google's official Wear OS partner in China) to jointly develop an ecosystem of "smart heart" and other consumer health applications for the Google Wear OS platform in China based on CardieX subsidiary, ATCOR, software and algorithms.